Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity.

Fiorot FJ, Islabão AG, Pereira RM, Terreri MT, Saad-Magalhães C, Novak GV, Molinari BC, Sakamoto AP, Aikawa NE, Campos LM, Peracchi OA, Appenzeller S, Ferriani VP, Silva MF, Fonseca AR, Sztajnbok FR, Paim LB, Fraga MM, Okuda EM, Bica BE, Sena EG, Moraes AJ, Rolim AM, Spelling PF, Scheibel IM, Cavalcanti AS, Matos EN, Robazzi TC, Guimarães LJ, Santos FP, Ramos VC, Carneiro-Sampaio M, Bonfá E, Silva CA; Brazilian Childhood-onset Systemic Lupus Erythematosus Group.

Clin Rheumatol. 2019 Jun 13. doi: 10.1007/s10067-019-04631-0. [Epub ahead of print]

PMID:
31209708
2.

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease.

Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G.

Aliment Pharmacol Ther. 2019 Jun;49(11):1401-1409. doi: 10.1111/apt.15250. Epub 2019 Apr 15.

PMID:
30983024
3.

Multivariate Prediction of Hippocampal Atrophy in Alzheimer's Disease.

Liedes H, Lötjönen J, Kortelainen JM, Novak G, van Gils M, Gordon MF; Alzheimer’s Disease Neuroimaging Initiative; and the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing.

J Alzheimers Dis. 2019;68(4):1453-1468. doi: 10.3233/JAD-180484.

PMID:
30909211
4.

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B.

Aliment Pharmacol Ther. 2019 Apr;49(7):880-889. doi: 10.1111/apt.15179. Epub 2019 Feb 19.

PMID:
30784100
5.

Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome.

Blay G, Rodrigues JC, Ferreira JCO, Leal GN, Gormezano NW, Novak GV, Pereira RMR, Terreri MT, Magalhães CS, Molinari BC, Sakamoto AP, Aikawa NE, Campos LMA, Fernandes TAP, Clemente G, Peracchi OAB, Bugni V, Marini R, Sacchetti SB, Carvalho LM, Fraga MM, Castro TCM, Ramos VC, Bonfá E, Silva CA; Brazilian Childhood-onset Systemic Lupus Erythematosus Group.

Adv Rheumatol. 2018 Nov 23;58(1):39. doi: 10.1186/s42358-018-0038-4.

PMID:
30657099
6.

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.

Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, Podhorna J, Serné E, Verbraak F, Yaqub M, Hillebrand A, Griffa A, Pendleton N, Kramer SE, Teunissen CE, Lammertsma A, Barkhof F, van Berckel BNM, Scheltens P, Muller M, Maier AB, Herholz K, Visser PJ.

BMC Geriatr. 2018 Nov 26;18(1):289. doi: 10.1186/s12877-018-0984-z.

7.

A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study.

Morrison RL, Pei H, Novak G, Kaufer DI, Welsh-Bohmer KA, Ruhmel S, Narayan VA.

Alzheimers Dement (Amst). 2018 Sep 27;10:647-656. doi: 10.1016/j.dadm.2018.08.010. eCollection 2018.

8.

Immunoglobulin G4-related disease with recurrent uveitis and kidney tumor mimicking childhood polyarteritis nodosa: a rare case report.

Nastri MMF, Novak GV, Sallum AEM, Campos LMA, Teixeira RAP, Silva CA.

Acta Reumatol Port. 2018 Jul-Sep;43(3):226-229.

9.

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, Engelborghs S, Van Broeckhoven C, Martinez-Lage P, Popp J, Tsolaki M, Verhey FRJ, Baird AL, Legido-Quigley C, Bertram L, Dobricic V, Zetterberg H, Lovestone S, Streffer J, Bianchetti S, Novak GP, Revillard J, Gordon MF, Xie Z, Wottschel V, Frisoni G, Visser PJ, Barkhof F.

Alzheimers Res Ther. 2018 Sep 27;10(1):100. doi: 10.1186/s13195-018-0428-1.

10.

Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?

Hindryckx P, Novak G.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:9-15. doi: 10.1016/j.bpg.2018.05.004. Epub 2018 Jun 20. Review.

PMID:
30060944
11.

Characteristics of 1555 childhood-onset lupus in three groups based on distinct time intervals to disease diagnosis: a Brazilian multicenter study.

Novak GV, Molinari BC, Ferreira JC, Sakamoto AP, Terreri MT, Pereira RMR, Saad-Magalhães C, Aikawa NE, Campos LM, Len CA, Appenzeller S, Ferriani VP, Silva MF, Oliveira SK, Islabão AG, Sztajnbok FR, Paim LB, Barbosa CM, Santos MC, Bica BE, Sena EG, Moraes AJ, Rolim AM, Spelling PF, Scheibel IM, Cavalcanti AS, Matos EN, Robazzi TC, Guimarães LJ, Santos FP, Silva CT, Bonfá E, Silva CA; Brazilian Childhood-onset Systemic Lupus Erythematosus Group.

Lupus. 2018 Sep;27(10):1712-1717. doi: 10.1177/0961203318787037. Epub 2018 Jul 18.

PMID:
30020023
12.

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.

Bos I, Vos SJB, Jansen WJ, Vandenberghe R, Gabel S, Estanga A, Ecay-Torres M, Tomassen J, den Braber A, Lleó A, Sala I, Wallin A, Kettunen P, Molinuevo JL, Rami L, Chetelat G, de la Sayette V, Tsolaki M, Freund-Levi Y, Johannsen P; Alzheimer's Disease Neuroimaging Initiative, Novak GP, Ramakers I, Verhey FR, Visser PJ.

Front Aging Neurosci. 2018 Jun 25;10:193. doi: 10.3389/fnagi.2018.00193. eCollection 2018.

13.

Success and safety of high infliximab trough levels in inflammatory bowel disease.

Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A.

Scand J Gastroenterol. 2018 Aug;53(8):940-946. doi: 10.1080/00365521.2018.1486882. Epub 2018 Jul 10.

PMID:
29987967
14.

Symptomatic polyautoimmunity at diagnosis of 1463 childhood-onset lupus: A Brazilian multicenter study.

Setoue DN, Pitta AC, Fiorot FJ, Nastri MM, Novak GV, Molinari BC, Oliveira JC, Gormezano NW, Sakamoto AP, Terreri MT, Pereira RM, Saad-Magalhães C, Sallum AM, Kozu K, Fraga MM, Piotto DP, Clemente G, Marini R, Gomes HR, Rabelo-Junior CN, Felix MM, Ribeiro MC, Almeida RG, Assad AP, Sacchetti SB, Barros LC, Bonfá E, Silva CA; Brazilian Childhood-onset Systemic Lupus Erythematosus Group.

Autoimmun Rev. 2018 Aug;17(8):836-839. doi: 10.1016/j.autrev.2018.03.009. Epub 2018 Jun 7.

PMID:
29885968
15.

Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment.

Wang D, Schultz T, Novak GP, Baker S, Bennett DA, Narayan VA.

J Alzheimers Dis. 2018;62(2):855-865. doi: 10.3233/JAD-170903.

16.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

PMID:
29429971
17.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

18.

Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations?

Valões CCM, Novak GV, Brunelli JB, Kozu KT, Toma RK, Silva CA.

Rev Bras Reumatol Engl Ed. 2017 Nov - Dec;57(6):521-525. doi: 10.1016/j.rbre.2016.09.011. Epub 2016 Oct 17. English, Portuguese.

19.

The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG.

J Crohns Colitis. 2018 Jan 5;12(1):105-119. doi: 10.1093/ecco-jcc/jjx117. Review.

PMID:
28961959
20.

Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource.

Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Gordon MF, Gungabissoon U, Mayer MA, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R.

Alzheimers Dement. 2018 Feb;14(2):130-139. doi: 10.1016/j.jalz.2017.06.2270. Epub 2017 Jul 21.

21.

Histologic scoring indices for evaluation of disease activity in Crohn's disease.

Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R.

Cochrane Database Syst Rev. 2017 Jul 21;7:CD012351. doi: 10.1002/14651858.CD012351.pub2. Review.

22.

Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.

Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S.

Clin Pharmacol Ther. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16. Review.

PMID:
28699217
23.

The frequency and influence of dementia risk factors in prodromal Alzheimer's disease.

Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, Lleó A, Alcolea D, Frisoni GB, Galluzzi S, Nobili F, Morbelli S, Drzezga A, Didic M, van Berckel BN, Salmon E, Bastin C, Dauby S, Santana I, Baldeiras I, de Mendonça A, Silva D, Wallin A, Nordlund A, Coloma PM, Wientzek A, Alexander M, Novak GP, Gordon MF; Alzheimer's Disease Neuroimaging Initiative, Wallin ÅK, Hampel H, Soininen H, Herukka SK, Scheltens P, Verhey FR, Visser PJ.

Neurobiol Aging. 2017 Aug;56:33-40. doi: 10.1016/j.neurobiolaging.2017.03.034. Epub 2017 Apr 8.

PMID:
28482212
24.

Chronic polyarthritis as the first manifestation of childhood systemic polyarteritis nodosa.

Novak GV, Hayashi K, Sampa K, Okumura Y, Ferreira GRV, Silva CA.

Einstein (Sao Paulo). 2017 Jan-Mar;15(1):96-99. doi: 10.1590/S1679-45082017RC3783. English, Portuguese.

25.

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology.

Westwood S, Liu B, Baird AL, Anand S, Nevado-Holgado AJ, Newby D, Pikkarainen M, Hallikainen M, Kuusisto J, Streffer JR, Novak G, Blennow K, Andreasson U, Zetterberg H, Smith U, Laakso M, Soininen H, Lovestone S.

Alzheimers Res Ther. 2017 Apr 26;9(1):31. doi: 10.1186/s13195-017-0258-6. Review.

26.

The safety of vedolizumab for the treatment of ulcerative colitis.

Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG.

Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5. Review.

PMID:
28276855
27.

Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG.

Drugs. 2017 Mar;77(4):379. doi: 10.1007/s40265-017-0719-z. No abstract available.

PMID:
28247265
28.

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG.

Drugs. 2017 Mar;77(4):363-377. doi: 10.1007/s40265-017-0693-5. Review. Erratum in: Drugs. 2017 Mar;77(4):379. Vipul, Jairath [corrected to Jairath, Vipul].

PMID:
28233275
29.

Disease-related and drug-induced skin manifestations in inflammatory bowel disease.

Hindryckx P, Novak G, Costanzo A, Danese S.

Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):203-214. doi: 10.1080/17474124.2017.1283985. Epub 2017 Feb 1. Review.

PMID:
28095714
30.

Review article: dose optimisation of infliximab for acute severe ulcerative colitis.

Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V.

Aliment Pharmacol Ther. 2017 Mar;45(5):617-630. doi: 10.1111/apt.13913. Epub 2017 Jan 11. Review.

31.

Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus.

Novak GV, Marques M, Balbi V, Gormezano NW, Kozu K, Sakamoto AP, Pereira RM, Terreri MT, Magalhães CS, Guariento A, Sallum AM, Marini R, Ferriani VP, Barbosa CM, de Castro TC, Ramos VC, Bonfá E, Silva CA.

Autoimmun Rev. 2017 Feb;16(2):132-135. doi: 10.1016/j.autrev.2016.12.004. Epub 2016 Dec 14. Review.

PMID:
27988434
32.

The effect of army vest design on the occurrence of stress fractures and overuse injuries in female military recruits.

Palmanovich E, Frankl M, Nyska M, Hetsroni I, Constantini N, Trejo L, Bechar R, Novak G, Lankovsky Z, Mann G.

J R Army Med Corps. 2017 Aug;163(4):251-254. doi: 10.1136/jramc-2016-000692. Epub 2016 Nov 30.

PMID:
27903837
33.

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G.

J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519.

PMID:
27589523
34.

[A NOVEL GENDER-SPECIFIC VEST FOR FEMALE INFANTRY RECRUITS DOES NOT REDUCE THE INCIDENCE OF OVERUSE PAIN SYNDROMES: A PROSPECTIVE RANDOMIZED STUDY AMONG 240 RECRUITS].

Palmanovich E, Frankl M, Hetsroni I, Nyska M, Maron N, Constantin N, Trejo L, Bechar R, Novak G, Lankovsky Z, Mann G.

Harefuah. 2016 Jun;155(6):357-9, 386. Hebrew.

PMID:
27544988
35.

The Impact of Aerosol Particle Mixing State on the Hygroscopicity of Sea Spray Aerosol.

Schill SR, Collins DB, Lee C, Morris HS, Novak GA, Prather KA, Quinn PK, Sultana CM, Tivanski AV, Zimmermann K, Cappa CD, Bertram TH.

ACS Cent Sci. 2015 Jun 24;1(3):132-41. doi: 10.1021/acscentsci.5b00174. Epub 2015 Jun 9.

36.

A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.

Ketter N, Liu E, Di J, Honig LS, Lu M, Novak G, Werth J, LePrince Leterme G, Shadman A, Brashear HR.

J Prev Alzheimers Dis. 2016;3(4):192-201. doi: 10.14283/jpad.2016.118.

PMID:
29199321
37.

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.

Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E.

J Alzheimers Dis. 2016;49(4):1123-34. doi: 10.3233/JAD-150448.

PMID:
26639957
38.

CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation.

Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA.

Eur J Pediatr. 2016 May;175(5):735-40. doi: 10.1007/s00431-015-2668-4. Epub 2015 Nov 14.

PMID:
26567544
39.

Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.

Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins RN, Maruff P, Masters CL, Romano G, Rowe CC, Savage G, Macaulay SL, Narayan VA; Alzheimer’s Disease Neuroimaging Initiative; AIBL Research Group.

J Alzheimers Dis. 2015;46(4):1079-89. doi: 10.3233/JAD-143015.

PMID:
26402634
40.

Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review.

Alexander M, Perera G, Ford L, Arrighi HM, Foskett N, Debove C, Novak G, Gordon MF.

J Alzheimers Dis. 2015;48(2):355-9. doi: 10.3233/JAD-150168. Review.

PMID:
26401999
41.

Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review.

Tang EY, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, Dufouil C, Brayne C, Robinson L, Launer LJ, Stephan BC.

PLoS One. 2015 Sep 3;10(9):e0136181. doi: 10.1371/journal.pone.0136181. eCollection 2015. Review.

42.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001. Review.

PMID:
26194317
43.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

44.

Occult spinal dysraphism: a challenge in pain management.

Gerges FJ, Manchanda C, Novak G, Al-Kimawi M, Semenovski M, Williams S.

Pain Physician. 2015 Mar-Apr;18(2):E225-8.

45.

Serum lipids in Brazilian children and adolescents: determining their reference intervals.

Slhessarenko N, Jacob CM, Azevedo RS, Fontes CJ, Novak GV, Andriolo A.

BMC Public Health. 2015 Jan 21;15:18. doi: 10.1186/s12889-015-1359-4.

46.

Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials.

Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;43(3):809-21. doi: 10.3233/JAD-131979.

PMID:
25114074
47.

Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.

Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L, Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J, Wang H, Wolz R, Stephenson D.

Alzheimers Dement. 2014 Jul;10(4):421-429.e3. doi: 10.1016/j.jalz.2013.07.003.

PMID:
24985687
48.

Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.

Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA.

Neuropsychiatr Dis Treat. 2014 May 24;10:929-52. doi: 10.2147/NDT.S62323. eCollection 2014.

49.

Postnatal maternal deprivation and pubertal stress have additive effects on dopamine D2 receptor and CaMKII beta expression in the striatum.

Novak G, Fan T, O'Dowd BF, George SR.

Int J Dev Neurosci. 2013 May;31(3):189-95. doi: 10.1016/j.ijdevneu.2013.01.001. Epub 2013 Jan 10.

PMID:
23313435
50.

Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease.

Novak G, Fan T, O'Dowd BF, George SR.

Synapse. 2013 Apr;67(4):179-88. doi: 10.1002/syn.21628. Epub 2012 Dec 27.

Supplemental Content

Support Center